$BTI

BTI Q2 2026 Earnings Call Transcript

British American Tobacco (BTI) reported Q2 2026 results, citing 2.9% group revenue growth at constant currency and a 7.9% rise in adjusted diluted EPS. Smokeless revenue was 19.8% of group revenue, with 35 million consumers. Heated product revenue fell 12%. Full-year EPS guidance was upgraded to the mid-point of a 5% to 8% range, alongside a GBP 1.3 billion 2026 buyback.

Original reporting
Published Aug 8, 2026, 9:46 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 4:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BTI Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$BTIBullishMed
01

Why it matters

Key items for trading are the upgraded full-year EPS guidance, expected lower net finance costs from debt repayment, and Fit2Win savings targets, alongside segment mix signals (smokeless share and U.S. vapour value share).

02

Market read

BTI’s call combines segment momentum (smokeless share near 20%), U.S. vapour legal-market growth claims, and a guidance upgrade, which can drive expectation revisions for earnings and margins.

03

What to watch

The transcript emphasizes phasing toward the second half and inventory movements; traders may discount near-term quality of earnings until cash conversion and margin delivery are confirmed in subsequent reporting.

Relevance 8/10Novelty 7/10Timing: earnings call transcript dated for July 30, 2026 results

Background

BTI’s Q2 2026 earnings call transcript outlines segment performance across smokeless (Modern Oral, Vapour, Heated) and combustibles, plus transformation and capital allocation updates.

Company-level read

Ticker impact

$BTIBullishMedium confidence
Context

British American Tobacco reported Q2 2026 transformation progress, including smokeless revenue share rising to 19.8% and upgraded full-year EPS guidance.

Expected impact

Moderately positive bias for BTI as guidance is upgraded and smokeless share and U.S. vapour enforcement-driven growth are highlighted.

Evidence & confidence

The article includes multiple management-stated datapoints (smokeless share, consumer growth, Fit2Win savings, and upgraded EPS range) that directly affect earnings power and segment mix, though it is a transcript rather than a fresh filing or print.

Market effects

Tobacco peers may see read-across on smokeless share gains, U.S. vapour enforcement dynamics, and the credibility of cost-savings programs like Fit2Win.

APMEA weakness is attributed to regulatory pressure and illicit volume, which could influence regional risk premia for other nicotine product operators.

If BTI’s U.S. vapour legal market expansion narrative holds, it can affect broader sentiment toward smokeless categories globally.

Counterpoint

Heated product revenue declines and APMEA regulatory/illicit-volume headwinds suggest the upgraded EPS may rely on execution and second-half regional recoveries rather than broad-based improvement.

Key entities

  • British American Tobacco p.l.c.

    Subject of the earnings call transcript, providing segment KPIs, transformation savings, and upgraded full-year EPS guidance.

  • Tadeu Marroco

    CEO who discussed transformation momentum, U.S. vapour enforcement effects, and product plans like Velo Max.

  • Javed Iqbal

    Interim CFO who covered financial performance drivers including net finance costs and Fit2Win optimization.

Related articles

$PMMed

Philip Morris (PM) Bets $1.2B on ZYN as BAT (BTI) Steps Up Its Pouch Push

Philip Morris International (PM) opened a $1.2B, 780,000 sq ft Aurora, Colorado campus to produce ZYN nicotine pouches, after about 19 months. The FDA authorized 20 ZYN products as modified risk tobacco products on June 30. Reuters also cited PM beating Q2 estimates. The article notes Aurora cost rose from $600M and highlights BAT (BTI) growth and planned Velo Max rollout.

$BTIMedAI 8/10

BRITISH AMERICAN TOBACCO PLC – British American Tobacco Announces Pricing of $1,500,000,000 Notes Offerings - Sens

British American Tobacco (BAT) said its wholly owned subsidiary B.A.T. Capital Corporation priced a $1.5 billion notes offering. It includes $750 million 5.300% notes due 2033 and $750 million 5.550% notes due 2036, guaranteed by BAT and other entities including Reynolds American Inc. Expected to close 5 Aug 2026. Net proceeds for general corporate purposes, including potential debt repayment.

$BTIMedAI 8/10

BTI Q2 2026 Earnings Call Transcript

British American Tobacco (BTI) Q2 2026 earnings call reported 2.9% group revenue growth at constant currency and a 7.9% rise in adjusted diluted EPS. New Category revenue grew 18%, with Modern Oral up 66%. Smokeless was 19.8% of revenue. Full-year EPS guidance was upgraded to the mid of 5% to 8%, with GBP 1.3bn buyback for 2026 and Fit2Win savings of GBP 700m by 2028.

$BTIMed

BTI Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Tadeu Marroco Interim Chief Financial Officer - Javed Iqbal Group Head of Investor Relations - Victoria Buxton TAKEAWAYS Group Revenue -- 2.9% growth at constant currency, reflecting multi-category performance in the U.S. and an acceleration in New Category growth. Adjusted Diluted EPS -- 7.9% increase, supported by lower net finance costs following debt repayment and 4.4% growth from earning kickers.

$BTIMed

BAT Lifts Annual Profit Growth Target As Velo Drives US Momentum

British American Tobacco (BAT) raised its full-year adjusted EPS growth outlook to the middle of its 5% to 8% medium-term range, up from earlier guidance at the low end, citing strong US momentum and demand for its Velo nicotine pouches, offsetting weaker Asia. It kept revenue and adjusted operating profit growth at the low end of 3% to 5% and 4% to 6%. Six-month adjusted EPS was 164p, up 7.9% vs a 158.5p consensus.